Primary Hypercholesterolemia Therapeutics
1. Crestor patent expiration
Treatment: Use of rosuvastatin calcium to reduce elevated total-c, ldl-c, apob, nonhdl-c or tg levels; To increase hdl-c in adult patients with primary hyperlipidemia or mixed dyslipidemia; And to slow the progr...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6858618 | ASTRAZENECA | Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia |
Dec, 2021
(4 years ago) | |
|
US6316460 (Pediatric) | ASTRAZENECA | Pharmaceutical compositions |
Feb, 2021
(4 years ago) | |
| US7030152 | ASTRAZENECA | Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease |
Apr, 2018
(7 years ago) | |
| US7964614 | ASTRAZENECA | Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease |
Apr, 2018
(7 years ago) | |
|
USRE37314 (Pediatric) | ASTRAZENECA | Pyrimidine derivatives |
Jul, 2016
(9 years ago) | |
| US6316460 | ASTRAZENECA | Pharmaceutical compositions |
Aug, 2020
(5 years ago) | |
|
US7030152 (Pediatric) | ASTRAZENECA | Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease |
Oct, 2018
(7 years ago) | |
|
US7964614 (Pediatric) | ASTRAZENECA | Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease |
Oct, 2018
(7 years ago) | |
|
US6858618 (Pediatric) | ASTRAZENECA | Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia |
Jun, 2022
(3 years ago) | |
| USRE37314 | ASTRAZENECA | Pyrimidine derivatives |
Jan, 2016
(10 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-573) | Nov 06, 2011 |
| New Indication(I-611) | Oct 16, 2012 |
| New Indication(I-621) | Feb 08, 2013 |
| Pediatric Exclusivity(PED) | Apr 16, 2013 |
| New Patient Population(NPP) | Nov 20, 2018 |
| New Indication(I-732) | May 27, 2019 |
| Orphan Drug Exclusivity(ODE) | May 27, 2023 |
| Orphan Drug Exclusivity(ODE-118) | May 27, 2023 |
Drugs and Companies using ROSUVASTATIN CALCIUM ingredient
Market Authorisation Date: 12 August, 2003
Dosage: TABLET
How can I launch a generic of CRESTOR before it's drug patent expiration?
More Information on Dosage
CRESTOR family patents
2. Leqvio patent expiration
Treatment: As an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (hefh) or clinical atherosclerotic cardiovascular disease (ascv...
LEQVIO's oppositions filed in EPO
LEQVIO IPR and PTAB Proceedings
Can you believe LEQVIO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11078485 | NOVARTIS | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Nov, 2023
(2 years ago) | |
| US9708610 | NOVARTIS | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Jan, 2024
(2 years ago) | |
| US9074213 | NOVARTIS | Compositions and methods for inhibiting expression of a target gene |
Mar, 2022
(3 years ago) | |
| US8232383 | NOVARTIS | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
Feb, 2023
(2 years ago) | |
| US8546143 | NOVARTIS | Compositions and methods for inhibiting expression of a target gene |
Apr, 2022
(3 years ago) | |
| US10125369 | NOVARTIS | PCSK9 iRNA compositions and methods of use thereof |
Aug, 2034
(8 years from now) | |
| US9370582 | NOVARTIS | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(2 years from now) | |
| US8106022 | NOVARTIS | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2029
(3 years from now) | |
| US11530408 | NOVARTIS | Therapeutic compositions |
May, 2024
(1 year, 7 months ago) | |
| US9708615 | NOVARTIS | Therapeutic compositions |
Mar, 2024
(1 year, 10 months ago) | |
| US10273477 | NOVARTIS | Therapeutic compositions |
Mar, 2024
(1 year, 10 months ago) | |
| US8828956 | NOVARTIS | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(2 years from now) | |
| US8809292 | NOVARTIS | Compositions and methods for inhibiting expression of the PCSK9 gene |
May, 2027
(1 year, 3 months from now) | |
| US10131907 | NOVARTIS | Glycoconjugates of RNA interference agents |
Aug, 2028
(2 years from now) | |
| US10806791 | NOVARTIS | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(2 years from now) | |
| US10669544 | NOVARTIS | Therapeutic compositions |
Mar, 2024
(1 year, 10 months ago) | |
| US12460206 | NOVARTIS | NA |
Aug, 2034
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10590418 | NOVARTIS | Methods and compositions for RNAi mediated inhibition of gene expression in mammals |
Jul, 2022
(3 years ago) | |
| US10266825 | NOVARTIS | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Nov, 2023
(2 years ago) | |
| US10851377 | NOVARTIS | Methods and compositions for treating a proprotein convertase subtilisin kexin (PCSK9) gene-associated disorder |
Aug, 2036
(10 years from now) | |
| US8222222 | NOVARTIS | Compositions and methods for inhibiting expression of the PCSK9 gene |
Dec, 2027
(1 year, 11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 22, 2026 |
Drugs and Companies using INCLISIRAN SODIUM ingredient
NCE-1 date: 22 December, 2025
Market Authorisation Date: 22 December, 2021
Dosage: SOLUTION
More Information on Dosage
LEQVIO family patents